Literature DB >> 17340039

Genetic variation in the B-type natiuretic peptide pathway affects BNP levels.

David E Lanfear1, Joshua M Stolker, Sharon Marsh, Michael W Rich, Howard L McLeod.   

Abstract

PURPOSE: The importance of B-type natriuretic peptide (BNP) as a diagnostic and therapeutic modality in cardiovascular disease is well known. BNP levels correlate clinical and physiologic characteristics, as well as outcomes. We sought to investigate the influence of BNP pathway genetic variation on BNP levels after adjustment for clinical/physiologic factors.
MATERIALS AND METHODS: DNA was extracted from 147 patients undergoing elective cardiac catheterization. Patients with elevated troponin were excluded. Detailed clinical data was collected including standard demographic, laboratory, echocardiographic and catheterization data. Genotype was determined at 19 loci in five genes relevant to the BNP pathway. Multivariable linear regression models of logBNP, adjusted for clinical variables, were used to assess the incremental influence of the genetic variants.
RESULTS: Natriuretic peptide precursor B gene (NPPB) variants incrementally improved models of logBNP after inclusion of clinical/physiologic parameters. The NPPB -381 T > C genotype was significantly associated with logBNP in the model (p = 0.0005), with the model predicting 50% lower BNP levels in otherwise similar T/T vs. C/C subjects. The NPPB 777 G > A (3' flanking region) genotype was of borderline significance (p = 0.0078). None of the other genotypes examined were significant (all p > 0.2).
CONCLUSIONS: Genetic variation in NPPB significantly impacts BNP levels after adjustment for clinical/physiologic factors. The full linear regression model predicted up to a 50% relative difference in BNP levels between NPPB -381 T > C genotype groups. This suggests that NPPB sequence variants affect BNP physiology, possibly via transcriptional regulation. Further studies are needed to define whether these variants impact the clinical interpretation of BNP levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17340039     DOI: 10.1007/s10557-007-6007-5

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  22 in total

1.  Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.

Authors:  David E Lanfear; Sheryl Chow; Badri Padhukasahasram; Jia Li; David Langholz; W H Wilson Tang; L Keoki Williams; Hani N Sabbah
Journal:  J Card Fail       Date:  2014-06-28       Impact factor: 5.712

2.  Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study.

Authors:  Deepak K Gupta; James A de Lemos; Colby R Ayers; Jarett D Berry; Thomas J Wang
Journal:  JACC Heart Fail       Date:  2015-06-10       Impact factor: 12.035

3.  Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study.

Authors:  Solomon K Musani; Ervin R Fox; Aldi Kraja; Aurelian Bidulescu; Wolfgang Lieb; Honghuang Lin; Ashley Beecham; Ming-Huei Chen; Janine F Felix; Caroline S Fox; W H Linda Kao; Sharon L R Kardia; Ching-Ti Liu; Mike A Nalls; Tatjana Rundek; Ralph L Sacco; Jennifer Smith; Yan V Sun; Gregory Wilson; Zhaogong Zhang; Thomas H Mosley; Herman A Taylor; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2015-01-05

4.  Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway.

Authors:  David E Lanfear; Bipin Sunkara; Jia Li; Sharad Rastogi; Ramesh C Gupta; Badri Padhukasahasram; L Keoki Williams; Hani N Sabbah
Journal:  J Cardiovasc Transl Res       Date:  2013-07-09       Impact factor: 4.132

5.  The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Syed Ameenuddin; Douglas W Mahoney; Joshua P Slusser; Denise M Heublein; Margaret M Redfield; Richard J Rodeheffer; Timothy M Olson; John C Burnett
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 6.  Genetic variation in the natriuretic peptide system and heart failure.

Authors:  David E Lanfear
Journal:  Heart Fail Rev       Date:  2008-10-11       Impact factor: 4.214

7.  LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice.

Authors:  Dan Lu; Hong Lian; Xiaojuan Zhang; Haitao Shao; Lan Huang; Chuan Qin; Lianfeng Zhang
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

8.  Does B-type natriuretic peptide or its gene polymorphism predict patient outcome after coronary artery bypass graft surgery?

Authors:  Hai Yu; Da Zhu; Bin Liu
Journal:  Anesthesiology       Date:  2009-12       Impact factor: 7.892

Review 9.  Natriuretic peptides in the diagnosis and management of chronic heart failure.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Clin       Date:  2009-10       Impact factor: 3.179

Review 10.  Genetics and pharmacogenetics in heart failure.

Authors:  Eric M Snyder; Thomas P Olson; Bruce D Johnson
Journal:  Curr Heart Fail Rep       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.